Skip to main content

Posts tagged with "The Dark Side"

  • Regulatory Affairs

    Act Now And We’ll Throw In This Dead Arachnid

    I have a couple of bad-behavior stories today. The first (via ChemJobber’s Twitter feed) is from the FDA. They were inspecting – well, OK, trying to inspect – a Japanese facility owned by Nippon Fine Chemical, supplying APIs (active pharmaceutical ingredients/intermediates) to both the US and Japanese markets. (Readers outside the… Read More
  • Business and Markets

    China’s Internal Drug Market: A Mess

    This story has been making the rounds the last few days, and it’s interesting on several levels. A report in the Chinese newspaper Economic Information Daily says that the Chinese SFDA (State Food and Drug Administration) has been conducting a review of Chinese clinical trial practices, and after reviewing 1,622 trials has found that most of… Read More
  • The Dark Side

    A Good Old Fashioned Election

    You’d think that if someone was going to rig an election for a scientific society, they’d be. . .well, more scientific about it than this. Science reports that the Society for Biological Inorganic Chemistry has invalidated their recent officer election because things looked just a tiny bit suspicious: Counting revealed far more votes th… Read More
  • Aging and Lifespan

    A Shady Trial?

    The “young blood” research field is moving right along, but there are reasons to wonder about some of the directions it’s moving in. I’m referring, of course, to the results that have shown profound effects of younger plasma on older animals, and the big question is what the effects are on older humans. The Stanford… Read More
  • Drug Development

    Let’s Just Declare This a Clinical Candidate, Shall We?

    A longtime reader sent along a discussion he’d had recently about the “December Effect”. That has different names in different companies, but it refers to a situation that many people (especially those working for a large drug company) have experienced. If you’re at one of those big companies, you have targets for how many… Read More
  • The Dark Side

    The University of Malaya Is Not Having It

    Much faster than I (or probably anyone) expected, the University of Malaya has investigated the papers written about here and here, and concluded that yes indeed, they are full of fraudulent images. Retraction Watch has the story here, and here’s the statement from the university. They’re asking the authors to immediately retract all th… Read More
  • The Dark Side

    Crap, Courtesy of a Major Scientific Publisher

    I hate to be like this. But yesterday a number of chemists began noticing this paper, and after having a look, I think it really needs to be mentioned. (Update: if that link is down, and it’s been spotty under all the attention, try this one). It’s a group from Kuala Lumpur, the pharmacology department… Read More
  • Analytical Chemistry

    Another Crashing Noise From the Basement

    In case you’ve missed, it, Theranos (the blood-testing company whose secretive technology has been taking some major blows over the last few months) has reached yet another unwelcome stage in its troubles. First you have people expressing doubts about the company’s product, then you have worries about their customers defecting, then you… Read More
  • Current Events

    No One Will Ever Suspect!

    Here’s another one of those “Let’s lift a bunch of material from the company we work for and start our own!” schemes: According to the indictment, Yu Xue and Lucy Xi were scientists working at GSK’s research facility in Upper Merion, Pa., when they engaged in an alleged scheme to steal trade secrets related to… Read More
  • Business and Markets

    Getting the Indian Drug Scandals Straight

    An old colleague of mine sent along this story from India. It’s about the problems that GVK Bio had in 2015, which led to all sorts of consequences: In October this year, a national newspaper in India ran a front page news item with the headline “A love story that cost GVK its international reputation”. The story… Read More